Navigation Links
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Date:6/2/2008

OR AKIVA, Israel, June 2 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) announced today the first commercial use of the CE certified Over and Under(R) Pericardium Covered Stent (PCS) in the UK

Over and Under(R) is a stent 100% covered with a heterologous tissue, designed to set a barrier between the coronary blood vessel wall and its lumen. It is intended for situations such as degenerated Saphenous Vein Graft (SVG), aneurysms and perforations.

The first Over and Under(R) PCS commercial implantation and first implantation in the UK was performed at the Royal Bournemouth Hospital whose Percutaneous Coronary Intervention Leader is Dr. Suneel Talwar and the procedure was performed by the Cath Lab director Dr. Rosie Swallow. The medical team granted the procedure as a success due to the special characteristics of the stent and the ease at which the stent was delivered to the lesion.

A pilot study designed to compare the deliverability of a PTFE covered stent vs. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head of Interventional Cardiology Unit and the company's medical director, at the annual EuroPCR meeting. Study was performed in phantom and porcine coronaries. Over and Under(R) PCS appeared to be significantly superior in deliverability in both model systems.

At its initial step, ITGI launched Over and Under(R) PCS in England, in collaboration with Pyramed, the UK distributor. "We are very pleased with Pyramed's marketing. They have recently purchased the stents and already managed to initiate its use," commented Efri Argaman, CEO of ITGI Medical, "The medical team's satisfaction strengthens our belief that Over and Under(R) PCS ushers in a new era for interventional medicine."

About Over and Under(R)

Over and Under(R) is a unique stent, first in a series of heterologous tissue covered stents, designed to set a barrier between the blood vessel wall and its lumen. Over and Under(R) PCS is indicated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

About ITGI Medical

ITGI medical is engaged with research and development, manufacturing and marketing of heterologous tissue covered stents. Over and Under(R) is the first among series of heterologous covered stents designed to treat coronary lesions and aneurysms.

Contact:

Danna Moran

Director of Marketing

ITGI Medical Ltd.

P: + 972-72-2200335

dannam@itgimedical.com


'/>"/>
SOURCE ITGI Medical LTD
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
8. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... LONDON , May 23, 2016 ... Boost Efficiency by 40% - Frontage Implement a Single ... Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... the United States and China ... deployed across its laboratory facilities. In addition to serving as the ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients found in ... malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols ...
(Date:5/20/2016)... ... ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, in malignant ... Surviving Mesothelioma has just posted an article on the new study. Click here ... study on the fact the Manumycin A, a derivative of Streptomyces parvulus, is known ...
(Date:5/19/2016)... , May 19, 2016  AdvancedFlow Systems Inc. ... (AGI), based out of Maple Ridge, ... Ltd. to its existing portfolio of contract manufacturing ... AFS along with its sister companies Surround Technologies ... vertically integrated industrial group that specializes in providing ...
Breaking Biology Technology:
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):